{"id":"bimatoprost-ophthalmic-solution","safety":{"commonSideEffects":[{"rate":"25-45","effect":"Conjunctival hyperemia (redness)"},{"rate":"10-25","effect":"Iris pigmentation increase"},{"rate":"3-10","effect":"Eyelash growth (hypertrichosis)"},{"rate":"10-20","effect":"Eye irritation/discomfort"},{"rate":"5-15","effect":"Foreign body sensation"}]},"_chembl":{"chemblId":"CHEMBL1200963","moleculeType":"Small molecule","molecularWeight":"415.57"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Bimatoprost mimics the action of prostaglandin F by activating F-prostanoid receptors on the ciliary muscle bundle and trabecular meshwork. This activation enhances drainage of aqueous humor through the uveoscleral (unconventional) pathway, reducing intraocular pressure. The drug is administered topically as an ophthalmic solution, allowing direct local action in the eye.","oneSentence":"Bimatoprost is a prostaglandin F analog that binds to prostaglandin F receptors in the eye to increase uveoscleral outflow of aqueous humor, thereby lowering intraocular pressure.","_ai_confidence":"high"},"_scrapedAt":"2026-03-27T23:43:00.208Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Glaucoma"},{"name":"Ocular hypertension"}]},"trialDetails":[{"nctId":"NCT04499248","phase":"PHASE1, PHASE2","title":"AGN-193408 SR in the Treatment of Open-angle Glaucoma or Ocular Hypertension","status":"RECRUITING","sponsor":"AbbVie","startDate":"2020-11-16","conditions":"Open-angle Glaucoma, Ocular Hypertension","enrollment":96},{"nctId":"NCT07218796","phase":"PHASE3","title":"Evaluation of the Safety and Efficacy of the Bimatoprost Implant System Used in Combination With the SpyGlass IOL Compared to Timolol Ophthalmic Solution (Rhone)","status":"RECRUITING","sponsor":"SpyGlass Pharma, Inc.","startDate":"2025-10-28","conditions":"Cataract, Glaucoma, Ocular Hypertension","enrollment":400},{"nctId":"NCT07218783","phase":"PHASE3","title":"Evaluation of the Safety and Efficacy of the Bimatoprost Implant System Used in Combination With the SpyGlass IOL Compared to Timolol Ophthalmic Solution (Rhine)","status":"RECRUITING","sponsor":"SpyGlass Pharma, Inc.","startDate":"2025-10-15","conditions":"Cataract, Glaucoma, Ocular Hypertension","enrollment":400},{"nctId":"NCT05938699","phase":"PHASE2, PHASE3","title":"Aqueous Humor Dynamics of NCX 470 Ophthalmic Solution","status":"COMPLETED","sponsor":"Nicox Ophthalmics, Inc.","startDate":"2023-12-12","conditions":"Open Angle Glaucoma","enrollment":18},{"nctId":"NCT06120842","phase":"PHASE1, PHASE2","title":"Evaluation of the Bimatoprost Implant System Used in Combination With the SpyGlass Intraocular Lens Compared to Timolol Ophthalmic Solution","status":"ACTIVE_NOT_RECRUITING","sponsor":"SpyGlass Pharma, Inc.","startDate":"2023-10-13","conditions":"Cataract, Glaucoma, Ocular Hypertension","enrollment":201},{"nctId":"NCT06761313","phase":"PHASE4","title":"Triplenex (triple Fixed Combination) Use Evaluation in Patients with Glaucoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"Federal University of São Paulo","startDate":"2021-03-01","conditions":"Glaucoma, Quality of Life (QOL)","enrollment":40},{"nctId":"NCT06267274","phase":"PHASE1","title":"A Randomized, Double-blind, Parallel-group, Two-arm, Multiple Dose, Multicenter, Bioequivalence Study With Clinical Endpoint in the Treatment of Subjects With Chronic Open-angle Glaucoma or Ocular Hypertension in Both Eyes","status":"RECRUITING","sponsor":"Amneal Pharmaceuticals, LLC","startDate":"2024-04-01","conditions":"Open-angle Glaucoma, Ocular Hypertension","enrollment":240},{"nctId":"NCT05397600","phase":"PHASE3","title":"Efficacy and Safety Assessment of T4032 (Unpreserved Bimatoprost 0.01%) Versus Lumigan® 0.01% in Ocular Hypertensive or Glaucomatous Patients","status":"COMPLETED","sponsor":"Laboratoires Thea","startDate":"2022-06-22","conditions":"Glaucoma, Ocular Hypertension","enrollment":684},{"nctId":"NCT03825380","phase":"PHASE3","title":"Efficacy and Safety Assessment of T4032 Versus Lumigan® in Ocular Hypertensive or Glaucomatous Patients","status":"COMPLETED","sponsor":"Laboratoires Thea","startDate":"2018-11-23","conditions":"Ocular Hypertension, Glaucoma","enrollment":485},{"nctId":"NCT05729594","phase":"PHASE1","title":"Systemic Pharmacokinetic Study of T4032 (Unpreserved Bimatoprost 0.01%) Eye Gel Versus Lumigan® 0.01% Eye Drops in 40 Healthy Volunteers","status":"COMPLETED","sponsor":"Laboratoires Thea","startDate":"2023-02-27","conditions":"Healthy Volunteers","enrollment":40},{"nctId":"NCT04898387","phase":"PHASE3","title":"Efficacy and Safety Assessment of T4030 Eye Drops Versus Ganfort® UD in Ocular Hypertensive or Glaucomatous Patients.","status":"COMPLETED","sponsor":"Laboratoires Thea","startDate":"2021-03-26","conditions":"Ocular Hypertension Glaucoma","enrollment":554},{"nctId":"NCT04890106","phase":"PHASE3","title":"Bioequivalence Study With Clinical Endpoint Comparing Bimatoprost Ophthalmic Solution 0.01% to LUMIGAN® In The Treatment of Chronic Open-Angle Glaucoma","status":"COMPLETED","sponsor":"Mankind Pharma Limited","startDate":"2021-10-02","conditions":"Glaucoma, Open-Angle","enrollment":310},{"nctId":"NCT05401357","phase":"PHASE3","title":"Bioequivalence Study With Clinical Endpoint Comparing Bimatoprost Ophthalmic Solution 0.01% and LUMIGAN® in the Treatment of Chronic Open-Angle Glaucoma or Ocular Hypertension in Both Eyes.","status":"RECRUITING","sponsor":"Amneal Pharmaceuticals, LLC","startDate":"2022-06-29","conditions":"Glaucoma, Open-Angle, Ocular Hypertension","enrollment":168},{"nctId":"NCT05241938","phase":"NA","title":"PSLT Compared to Prostaglandin Analogue Eye Drops","status":"UNKNOWN","sponsor":"Federal University of Rio Grande do Sul","startDate":"2021-09-01","conditions":"Open Angle Glaucoma, Ocular Hypertension","enrollment":75},{"nctId":"NCT03284853","phase":"PHASE3","title":"Safety and Efficacy Study of PG324 (Netarsudil/Latanoprost 0.02% / 0.005%) Ophthalmic Solution Compared to GANFORT® Ophthalmic Solution in Open Angle Glaucoma or Ocular Hypertension","status":"COMPLETED","sponsor":"Aerie Pharmaceuticals","startDate":"2017-09-05","conditions":"Open Angle Glaucoma, Ocular Hypertension","enrollment":436},{"nctId":"NCT03927443","phase":"PHASE3","title":"A Comparative Study of SPARC's SDP-133 Once Daily and Lumigan in Subjects With Open Angle Glaucoma or Ocular Hypertension","status":"WITHDRAWN","sponsor":"Sun Pharmaceutical Industries Limited","startDate":"2019-06-10","conditions":"Open Angle Glaucoma, Ocular Hypertension","enrollment":""},{"nctId":"NCT04896125","phase":"","title":"Comparison of Different Drugs on Ocular Surface Disease in Glaucoma Patients: a Prospective Randomised Study","status":"UNKNOWN","sponsor":"National Taiwan University Hospital","startDate":"2019-10-02","conditions":"Glaucoma; Ocular Disorders (I.E. Caused by Ocular Disorders)","enrollment":300},{"nctId":"NCT02830776","phase":"EARLY_PHASE1","title":"Topical Bimatoprost for Chemical Blepharoplasty","status":"COMPLETED","sponsor":"Tulane University","startDate":"2016-11","conditions":"Dermatochalasis","enrollment":15},{"nctId":"NCT00847483","phase":"PHASE4","title":"Comparison of Latanoprost With Travoprost and Bimatoprost in Patients With Elevated IOP. A 12-weeks, Masked Evaluator, Phase IV Multi-center Study in the US","status":"COMPLETED","sponsor":"Pfizer's Upjohn has merged with Mylan to form Viatris Inc.","startDate":"2002-01","conditions":"Glaucoma, Ocular Hypertension","enrollment":375},{"nctId":"NCT03292796","phase":"PHASE2","title":"RCT to Investigate if Prostaglandin Analogue Drops Increase the Risk of Cystoid Macular Oedema After Cataract Surgery.","status":"COMPLETED","sponsor":"Julie Dawson","startDate":"2016-12-07","conditions":"Open Angle Glaucoma and Cataract","enrollment":56},{"nctId":"NCT00999557","phase":"NA","title":"Bimatoprost Ophthalmic Solution in Increasing Eyebrow and Eyelash Growth in Patients Who Have Undergone Chemotherapy for Breast Cancer and in Healthy Participants","status":"WITHDRAWN","sponsor":"Jonsson Comprehensive Cancer Center","startDate":"2016-01","conditions":"Alopecia, Breast Cancer","enrollment":""},{"nctId":"NCT02358369","phase":"PHASE2","title":"Dose-Ranging Study of the Bimatoprost Ocular Insert","status":"COMPLETED","sponsor":"ForSight Vision5, Inc.","startDate":"2015-01-19","conditions":"Primary Open-Angle Glaucoma, Ocular Hypertension","enrollment":156},{"nctId":"NCT04380025","phase":"NA","title":"Mirtogenol and Bimatoprost on IOP in Hispanics With Open-Angle Glaucoma","status":"UNKNOWN","sponsor":"University of Puerto Rico","startDate":"2020-05-15","conditions":"Glaucoma","enrollment":72},{"nctId":"NCT02017327","phase":"PHASE4","title":"Safety and Efficacy Assessment of Monoprost® in Comparison With Lumigan® 0.01 % and Lumigan® 0.03% Unit Dose","status":"COMPLETED","sponsor":"Laboratoires Thea","startDate":"2013-12","conditions":"Primary Open Angle Glaucoma, Ocular Hypertension","enrollment":379},{"nctId":"NCT01157364","phase":"PHASE1, PHASE2","title":"Safety and Efficacy of a New Ophthalmic Formulation of Bimatoprost in Patients With Open Angle Glaucoma and Ocular Hypertension","status":"COMPLETED","sponsor":"Allergan","startDate":"2010-09-23","conditions":"Open-Angle Glaucoma, Ocular Hypertension","enrollment":109},{"nctId":"NCT02448043","phase":"NA","title":"Cutaneous Prostaglandin Application: Nail Growth, Nail Brittleness, and Eye Pressure","status":"COMPLETED","sponsor":"Northwestern University","startDate":"2015-06-04","conditions":"Nail Growth Cessation, Intraocular Pressure","enrollment":45},{"nctId":"NCT03966560","phase":"PHASE4","title":"Choroidal Thickness and Its Correlations With Ocular Parameters in Primary Open-angle Glaucoma","status":"COMPLETED","sponsor":"Afyon Kocatepe University Hospital","startDate":"2014-01","conditions":"Glaucoma, Open-Angle","enrollment":96},{"nctId":"NCT00440011","phase":"PHASE4","title":"Bimatoprost 0.03% Versus Travoprost 0.004% in Patients Currently on Latanoprost 0.005%","status":"COMPLETED","sponsor":"Allergan","startDate":"2006-08","conditions":"Glaucoma, Ocular Hypertension","enrollment":266},{"nctId":"NCT01170884","phase":"PHASE4","title":"Comparing Safety and Efficacy of Combigan® and Lumigan® With Lumigan® Alone in Glaucoma or Ocular Hypertension Subjects Treated With Xalatan®","status":"COMPLETED","sponsor":"Allergan","startDate":"2009-12","conditions":"Glaucoma, Ocular Hypertension","enrollment":121},{"nctId":"NCT00539526","phase":"PHASE4","title":"Evaluation of Hyperemia With the Use of Ocular Prostaglandin Analogues","status":"COMPLETED","sponsor":"Allergan","startDate":"2007-09","conditions":"Open Angle Glaucoma, Ocular Hypertension","enrollment":106},{"nctId":"NCT00538304","phase":"PHASE2","title":"A Study of the Safety and Efficacy of Bimatoprost in Patients With Glaucoma or Ocular Hypertension","status":"COMPLETED","sponsor":"Allergan","startDate":"2007-11","conditions":"Glaucoma, Ocular Hypertension","enrollment":222},{"nctId":"NCT01853085","phase":"","title":"A Study of Patients With Primary Open Angle Glaucoma or Ocular Hypertension Switched to Lumigan® UD Monotherapy for Medical Reasons","status":"COMPLETED","sponsor":"Allergan","startDate":"2013-04-01","conditions":"Glaucoma, Primary Open Angle, Ocular Hypertension","enrollment":1830},{"nctId":"NCT01243567","phase":"PHASE4","title":"Safety and Efficacy of Bimatoprost/Timolol Fixed Combination Versus Latanoprost in Patients With Open-Angle Glaucoma Who Have Never Been Treated","status":"COMPLETED","sponsor":"Allergan","startDate":"2010-06-01","conditions":"Glaucoma, Open-Angle","enrollment":81},{"nctId":"NCT01068964","phase":"NA","title":"Safety and Efficacy of Bimatoprost Timolol Ophthalmic Solution in Patients With Open Angle Glaucoma or Ocular Hypertension","status":"COMPLETED","sponsor":"Allergan","startDate":"2010-02-01","conditions":"Open-angle Glaucoma, Ocular Hypertension","enrollment":235},{"nctId":"NCT01099774","phase":"PHASE3","title":"Safety and Efficacy of Different Formulations of Bimatoprost Ophthalmic Solution in Patients With Glaucoma or Ocular Hypertension","status":"COMPLETED","sponsor":"Allergan","startDate":"2010-05-01","conditions":"Glaucoma, Ocular Hypertension","enrollment":597},{"nctId":"NCT01023841","phase":"PHASE4","title":"Safety and Efficacy of Bimatoprost Solution in Treating Eyelash Loss or Hypotrichosis in Children","status":"COMPLETED","sponsor":"Allergan","startDate":"2010-06-01","conditions":"Eyelash Hypotrichosis, Alopecia Areata","enrollment":71},{"nctId":"NCT02537015","phase":"PHASE2","title":"An Open-label Extension Study to Evaluate the Safety of the 13 mg Bimatoprost Ocular Insert","status":"COMPLETED","sponsor":"ForSight Vision5, Inc.","startDate":"2015-08-10","conditions":"Primary Open-Angle Glaucoma, Ocular Hypertension","enrollment":81},{"nctId":"NCT02143843","phase":"PHASE2","title":"An Open-Label Extension Study to Evaluate the Safety of the ForSight VISION5 Product","status":"COMPLETED","sponsor":"ForSight Vision5, Inc.","startDate":"2014-06-05","conditions":"Primary Open-Angle Glaucoma, Ocular Hypertension","enrollment":75},{"nctId":"NCT02176356","phase":"PHASE4","title":"Patient Satisfaction Study of Combined Facial Treatment With BOTOX® Cosmetic, JUVÉDERM® and LATISSE® (HARMONY Study)","status":"COMPLETED","sponsor":"Allergan","startDate":"2014-06-30","conditions":"Facial Rhytides, Crow's Feet Lines, Glabellar Lines","enrollment":116},{"nctId":"NCT02419508","phase":"PHASE4","title":"SIMBRINZA® Suspension BID as an Adjunctive to Prostaglandin Analogue (PGA)","status":"COMPLETED","sponsor":"Alcon Research","startDate":"2015-08-07","conditions":"Open-Angle Glaucoma, Ocular Hypertension","enrollment":290},{"nctId":"NCT01298700","phase":"PHASE4","title":"Long-Term Safety of Bimatoprost Ophthalmic Solution in Patients With Glaucoma or Ocular Hypertension","status":"COMPLETED","sponsor":"Allergan","startDate":"2011-05-31","conditions":"Glaucoma, Ocular Hypertension","enrollment":806},{"nctId":"NCT02863705","phase":"PHASE4","title":"Efficacy and Safety of COMBIGAN® in Korean Patients With Primary Open Angle Glaucoma (POAG) and Normal Tension Glaucoma (NTG)","status":"COMPLETED","sponsor":"Allergan","startDate":"2016-07-05","conditions":"Glaucoma, Open-Angle, Normal Tension Glaucoma","enrollment":118},{"nctId":"NCT02571712","phase":"PHASE4","title":"Safety of GANFORT® Ophthalmic Solution in Chinese Patients With Open-angle Glaucoma or Ocular Hypertension","status":"COMPLETED","sponsor":"Allergan","startDate":"2015-11-10","conditions":"Glaucoma, Open-Angle, Ocular Hypertension","enrollment":750},{"nctId":"NCT01927406","phase":"PHASE4","title":"The Secondary Beneficial Effects of Prostaglandin Analog Treatment in Thyroid Eye Disease Patients.","status":"WITHDRAWN","sponsor":"Stanford University","startDate":"2014-06","conditions":"Thyroid Eye Disease, Ocular Hypertension, Glaucoma","enrollment":""},{"nctId":"NCT01915940","phase":"PHASE2","title":"Bimatoprost Ocular Insert Compared to Topical Timolol Solution in Patients With Glaucoma or Ocular Hypertension","status":"COMPLETED","sponsor":"ForSight Vision5, Inc.","startDate":"2013-10-23","conditions":"Primary Open-Angle Glaucoma, Ocular Hypertension","enrollment":169},{"nctId":"NCT03487042","phase":"PHASE4","title":"Bimatoprost 0.03% Solution With NB-UVB Versus Their Use With Fractional Carbon Dioxide Laser in Treatment of Generalized Vitiligo","status":"UNKNOWN","sponsor":"Assiut University","startDate":"2018-05","conditions":"Generalized Vitiligo","enrollment":40},{"nctId":"NCT01535768","phase":"PHASE4","title":"Effect of Prophylactic Aqueous Suppression on Hyperencapsulation of Ahmed Glaucoma Valves","status":"UNKNOWN","sponsor":"Credit Valley EyeCare","startDate":"2012-02","conditions":"Glaucoma","enrollment":150},{"nctId":"NCT01217606","phase":"PHASE3","title":"Safety and Efficacy of Triple Combination Therapy in Patients With Primary Open-Angle Glaucoma or Ocular Hypertension","status":"COMPLETED","sponsor":"Allergan","startDate":"2011-01","conditions":"Glaucoma, Open-Angle, Ocular Hypertension","enrollment":185},{"nctId":"NCT01230736","phase":"PHASE4","title":"Safety and Efficacy of Changing to DuoTrav From Prior Therapy","status":"COMPLETED","sponsor":"Alcon Research","startDate":"2010-10","conditions":"Glaucoma","enrollment":105},{"nctId":"NCT02471105","phase":"PHASE4","title":"Investigation of IOP and Tolerability of Bimatoprost 0.01% and Tafluprost Unit Dose Preservative Free 15 Microgram/ml","status":"UNKNOWN","sponsor":"Universitaire Ziekenhuizen KU Leuven","startDate":"2015-09","conditions":"Ocular Hypertension, Glaucoma","enrollment":67},{"nctId":"NCT02059655","phase":"PHASE4","title":"Prostaglandin F2-alpha Eye Drops in Thyroid Eye Disease (Bima Study)","status":"COMPLETED","sponsor":"Cardiff University","startDate":"2014-11","conditions":"Graves' Ophthalmopathy","enrollment":31},{"nctId":"NCT00705757","phase":"PHASE4","title":"The Effects of Xalatan, Travatan and Lumigan on Skin Pigmentation Near the Eye","status":"COMPLETED","sponsor":"Summa Health System","startDate":"2008-03","conditions":"Glaucoma, Application Site Pigmentation Changes","enrollment":89},{"nctId":"NCT02097719","phase":"PHASE4","title":"Efficacy and Safety Study of Bimatoprost 0.01% Alone Compared With Travoprost 0.004% and Timolol 0.5% in Subjects With Glaucoma or Ocular Hypertension","status":"COMPLETED","sponsor":"Allergan","startDate":"2014-05","conditions":"Glaucoma, Ocular Hypertension","enrollment":100},{"nctId":"NCT01881126","phase":"PHASE4","title":"An Efficacy and Safety Study of Bimatoprost 0.01% Alone Compared With Travoprost 0.004% and Timolol 0.5% in Subjects With Glaucoma or Ocular Hypertension","status":"COMPLETED","sponsor":"Allergan","startDate":"2013-06","conditions":"Glaucoma, Ocular Hypertension","enrollment":93},{"nctId":"NCT01975714","phase":"PHASE4","title":"Intraocular Pressure and Tolerability Study of Preservative-free Prostaglandins (Bimatoprost and Latanoprost) on Glaucoma and Ocular Hypertension: European, Multicentric, Investigator-led, Single Masked Study","status":"COMPLETED","sponsor":"Association for Innovation and Biomedical Research on Light and Image","startDate":"2013-10","conditions":"Glaucoma, Ocular Hypertension","enrollment":67},{"nctId":"NCT01426113","phase":"PHASE3","title":"A Study of the Safety and Efficacy of Bimatoprost Ophthalmic Solution in Paediatric Patients With Glaucoma","status":"TERMINATED","sponsor":"Allergan","startDate":"2011-09","conditions":"Glaucoma","enrollment":6},{"nctId":"NCT01976624","phase":"","title":"Safety and Efficacy of Bimatoprost/Timolol (Ganfort®) Ophthalmic Solution in Korea","status":"COMPLETED","sponsor":"Allergan","startDate":"2009-08","conditions":"Glaucoma, Open-Angle, Ocular Hypertension","enrollment":756},{"nctId":"NCT01664039","phase":"PHASE4","title":"An Efficacy and Tolerability Study of TRAVATAN® Versus LUMIGAN®","status":"COMPLETED","sponsor":"Alcon Research","startDate":"2012-09","conditions":"Glaucoma, Ocular Hypertension","enrollment":104},{"nctId":"NCT01016691","phase":"PHASE2","title":"Safety and Efficacy of a Drug Delivery System in Glaucoma","status":"COMPLETED","sponsor":"Vistakon Pharmaceuticals","startDate":"2009-10","conditions":"Open-angle Glaucoma, Ocular Hypertension","enrollment":47},{"nctId":"NCT01698554","phase":"PHASE3","title":"Bimatoprost in the Treatment of Eyelash Hypotrichosis","status":"COMPLETED","sponsor":"Allergan","startDate":"2012-11","conditions":"Idiopathic Eyelash Hypotrichosis","enrollment":464},{"nctId":"NCT01863953","phase":"PHASE2","title":"A Safety and Efficacy Study of Fixed-Combination Bimatoprost and Brimonidine in Chronic Glaucoma or Ocular Hypertension","status":"COMPLETED","sponsor":"Allergan","startDate":"2013-06","conditions":"Glaucoma, Ocular Hypertension","enrollment":112},{"nctId":"NCT02138461","phase":"","title":"Tolerability of Bimatoprost 0.01% vs Latanoprost Eye Drops","status":"COMPLETED","sponsor":"MDbackline, LLC","startDate":"2013-10","conditions":"Glaucoma","enrollment":211},{"nctId":"NCT01241240","phase":"PHASE3","title":"Safety and Efficacy of Triple Combination Therapy in Patients With Primary Open-Angle Glaucoma or Ocular Hypertension","status":"COMPLETED","sponsor":"Allergan","startDate":"2011-03","conditions":"Glaucoma, Open-Angle, Ocular Hypertension","enrollment":192},{"nctId":"NCT02170662","phase":"PHASE2","title":"Topical Bimatoprost Effect on Androgen Dependent Hair Follicles","status":"COMPLETED","sponsor":"Duke University","startDate":"2009-11","conditions":"Male Pattern Hair Loss, Androgenetic Alopecia","enrollment":33},{"nctId":"NCT01547598","phase":"PHASE4","title":"Safety and Efficacy of LUMIGAN® RC Versus DuoTrav® in Patients Who Require Further Intraocular Pressure (IOP) Reduction","status":"COMPLETED","sponsor":"Allergan","startDate":"2011-12","conditions":"Glaucoma, Open-Angle, Ocular Hypertension","enrollment":135},{"nctId":"NCT01110499","phase":"PHASE2","title":"Safety and Efficacy of AGN-210961 Ophthalmic Solution Compared With Bimatoprost Ophthalmic Solution in Patients With Glaucoma or Ocular Hypertension","status":"COMPLETED","sponsor":"Allergan","startDate":"2010-06","conditions":"Ocular Hypertension, Primary Open-Angle Glaucoma","enrollment":163},{"nctId":"NCT01646151","phase":"","title":"A Study Comparing IOP-Lowering Treatments to Bimatoprost in Patients With Primary Open Angle Glaucoma or Ocular Hypertension","status":"COMPLETED","sponsor":"Allergan","startDate":"2012-05","conditions":"Glaucoma, Open-Angle, Ocular Hypertension","enrollment":2580},{"nctId":"NCT01589510","phase":"","title":"A Study of Lumigan® 0.01% in Patients With Primary Open Angle Glaucoma (POAG) or Ocular Hypertension (OHT)","status":"COMPLETED","sponsor":"Allergan","startDate":"2012-04","conditions":"Glaucoma, Open-Angle, Ocular Hypertension","enrollment":419},{"nctId":"NCT01493427","phase":"PHASE4","title":"Efficacy of Changing to TRAVATAN® From Prior Therapy","status":"COMPLETED","sponsor":"Alcon Research","startDate":"2011-12","conditions":"Open-Angle Glaucoma, Ocular Hypertension","enrollment":202},{"nctId":"NCT01489670","phase":"","title":"Observational Study of Lumigan® 0.01% Treatment for Patients With Primary Open Angle Glaucoma or Ocular Hypertension","status":"COMPLETED","sponsor":"Allergan","startDate":"2011-09","conditions":"Glaucoma, Open-Angle, Ocular Hypertension","enrollment":387},{"nctId":"NCT01327599","phase":"PHASE4","title":"Efficacy of Changing to DUOTRAV® From Prior Therapy","status":"COMPLETED","sponsor":"Alcon Research","startDate":"2011-08","conditions":"Open-Angle Glaucoma, Ocular Hypertension, Pigment Dispersion Glaucoma","enrollment":60},{"nctId":"NCT01525173","phase":"PHASE4","title":"A Safety and Efficacy Study of ALPHAGAN® P and LUMIGAN® in Subjects Previously Treated With Latanoprost for Glaucoma and Ocular Hypertension","status":"COMPLETED","sponsor":"Allergan","startDate":"2012-01","conditions":"Glaucoma, Ocular Hypertension","enrollment":137},{"nctId":"NCT01978015","phase":"PHASE4","title":"Blood-aqueous Barrier Changes After the Use of Timolol and Prostaglandin Analogues Fixed Combination in Pseudophakic Patients With POAG","status":"COMPLETED","sponsor":"University of Campinas, Brazil","startDate":"2011-10","conditions":"Uveitis, Anterior, Cystoid Macular Edema","enrollment":69},{"nctId":"NCT01291108","phase":"PHASE2","title":"Safety and Efficacy of AGN-210669 Ophthalmic Solution Compared With Bimatoprost Ophthalmic Solution in Patients With Open-Angle Glaucoma or Ocular Hypertension","status":"COMPLETED","sponsor":"Allergan","startDate":"2011-04","conditions":"Glaucoma, Open-Angle, Ocular Hypertension","enrollment":125},{"nctId":"NCT00693420","phase":"PHASE3","title":"Safety and Efficacy of Bimatoprost Solution in Increasing Overall Eyelash Prominence","status":"COMPLETED","sponsor":"Allergan","startDate":"2007-04","conditions":"Eyelashes","enrollment":278},{"nctId":"NCT00809848","phase":"PHASE1, PHASE2","title":"Safety and Efficacy of AGN 210669 Ophthalmic Solution in Patients With Ocular Hypertension or Primary Open-Angle Glaucoma","status":"COMPLETED","sponsor":"Allergan","startDate":"2009-02","conditions":"Ocular Hypertension, Glaucoma","enrollment":172},{"nctId":"NCT01001195","phase":"PHASE2","title":"Safety and Efficacy of Three Formulations of AGN-210669 Ophthalmic Solution Compared With Bimatoprost Ophthalmic Solution","status":"COMPLETED","sponsor":"Allergan","startDate":"2009-11","conditions":"Glaucoma, Open-Angle, Ocular Hypertension","enrollment":165},{"nctId":"NCT01568008","phase":"","title":"Observational Study of Lumigan® 0.01% for Treatment of Primary Open Angle Glaucoma (POAG) or Ocular Hypertension (OHT)","status":"COMPLETED","sponsor":"Allergan","startDate":"2011-10","conditions":"Open-Angle Glaucoma, Ocular Hypertension","enrollment":933},{"nctId":"NCT01216943","phase":"PHASE3","title":"Safety and Efficacy of Triple Combination Therapy in Patients With Glaucoma or Ocular Hypertension","status":"COMPLETED","sponsor":"Allergan","startDate":"2010-11","conditions":"Glaucoma, Ocular Hypertension","enrollment":126},{"nctId":"NCT01464424","phase":"PHASE4","title":"Assessment of Intraocular Pressure (IOP) Control in Subjects With Open-Angle Glaucoma or Ocular Hypertension Treated With Travoprost 0.004% (TRAVATAN® Z) or Bimatoprost 0.01% (LUMIGAN®)","status":"COMPLETED","sponsor":"Alcon Research","startDate":"2011-10","conditions":"Glaucoma, Ocular Hypertension, Open-Angle Glaucoma","enrollment":84},{"nctId":"NCT01448525","phase":"PHASE4","title":"Study Assessing Patient Satisfaction With LATISSE® for Increasing Eyelash Prominence","status":"COMPLETED","sponsor":"Allergan","startDate":"2011-10","conditions":"Hypotrichosis","enrollment":88},{"nctId":"NCT01177098","phase":"PHASE3","title":"Safety and Efficacy of a New Formulation of Bimatoprost/Timolol Ophthalmic Solution Compared With Bimatoprost/Timolol Ophthalmic Solution in Patients With Glaucoma or Ocular Hypertension","status":"COMPLETED","sponsor":"Allergan","startDate":"2010-10","conditions":"Glaucoma, Ocular Hypertension","enrollment":561},{"nctId":"NCT01253902","phase":"PHASE4","title":"Ocular Surface Tolerability Study of Prostaglandin Analogues in Patients With Open-Angle Glaucoma or Ocular Hypertension","status":"COMPLETED","sponsor":"Allergan","startDate":"2010-12","conditions":"Glaucoma, Open-Angle, Ocular Hypertension","enrollment":164},{"nctId":"NCT00907426","phase":"PHASE3","title":"Safety and Efficacy Study of Bimatoprost to Treat Hypotrichosis of the Eyelashes After Application to the Eyelid Margin","status":"COMPLETED","sponsor":"Allergan","startDate":"2009-08","conditions":"Hypotrichosis","enrollment":368},{"nctId":"NCT01655758","phase":"PHASE4","title":"24-hour Control of Intraocular Pressure (IOP) in Ocular Hypertension","status":"COMPLETED","sponsor":"University of Parma","startDate":"2002-01","conditions":"Ocular Hypertension","enrollment":61},{"nctId":"NCT01255306","phase":"","title":"The Influence of Silicone Oil on Nerve Fiber Layer Thickness After Pars Plana Vitrectomy","status":"COMPLETED","sponsor":"University Hospital Sestre Milosrdnice","startDate":"2010-04","conditions":"Rhegmatogenous Retinal Detachment, Toxic Effect of Silicone, Glaucoma Due to Silicon Oil","enrollment":60},{"nctId":"NCT00958035","phase":"PHASE4","title":"Study of Bimatoprost Solution in Increasing Eyelash Prominence in African Americans With Eyelash Hypotrichosis","status":"COMPLETED","sponsor":"Allergan","startDate":"2009-11","conditions":"Hypotrichosis","enrollment":89},{"nctId":"NCT01064882","phase":"PHASE2","title":"Safety and Efficacy of Bimatoprost Ophthalmic Solution in Increasing Eyelash Prominence","status":"COMPLETED","sponsor":"Allergan","startDate":"2010-03","conditions":"Eyelash Hypotrichosis","enrollment":104},{"nctId":"NCT00541242","phase":"PHASE4","title":"Safety and Efficacy of Bimatoprost Compared With Latanoprost in Patients With Glaucoma or Ocular Hypertension","status":"COMPLETED","sponsor":"Allergan","startDate":"2007-12","conditions":"Ocular Hypertension, Glaucoma","enrollment":586},{"nctId":"NCT01202513","phase":"PHASE4","title":"Topical Bimatoprost Solution 0.03%in Stable Vitiligo","status":"WITHDRAWN","sponsor":"Gian Sagar Medical College and Hospital","startDate":"2010-08","conditions":"Vitiligo, Repigmentation","enrollment":20},{"nctId":"NCT01168414","phase":"PHASE3","title":"A Study of Ganfort Versus Duotrav in Patients With Primary Open Angle Glaucoma or Ocular Hypertension","status":"COMPLETED","sponsor":"Ministry of Health, Malaysia","startDate":"2010-08","conditions":"Ocular Hypertension, Primary Open Angle Glaucoma","enrollment":42},{"nctId":"NCT00187577","phase":"NA","title":"Efficacy Study of Latanoprost and Bimatoprost Solutions in Promoting Eyelash Growth in Patients With Alopecia Areata","status":"COMPLETED","sponsor":"University of California, San Francisco","startDate":"2005-06","conditions":"Alopecia Areata","enrollment":14},{"nctId":"NCT01361841","phase":"NA","title":"Effects of Latanoprost, Bimatoprost and Travoprost in Patients With Latanoprost-resistant Glaucoma","status":"UNKNOWN","sponsor":"Centre de recherche du Centre hospitalier universitaire de Sherbrooke","startDate":"2009-01","conditions":"Ocular Hypertension, Primary Glaucoma","enrollment":141},{"nctId":"NCT00651859","phase":"PHASE2","title":"Safety and Efficacy Study of Bimatoprost in Ethnically Japanese Patients With Open-Angle Glaucoma or Ocular Hypertension","status":"COMPLETED","sponsor":"Allergan","startDate":"2002-11","conditions":"Glaucoma, Ocular Hypertension","enrollment":111},{"nctId":"NCT00652496","phase":"PHASE2","title":"Safety and Efficacy Study of Different Formulations of Bimatoprost Once-Daily in Patients With Glaucoma or Ocular Hypertension","status":"COMPLETED","sponsor":"Allergan","startDate":"2005-01","conditions":"Glaucoma, Ocular Hypertension","enrollment":249},{"nctId":"NCT00355446","phase":"PHASE4","title":"Bioavailability of Bimatoprost Ophthalmic Solution in Human Aqueous.","status":"COMPLETED","sponsor":"Indiana University School of Medicine","startDate":"2001-07","conditions":"Cataract","enrollment":48}],"_emaApprovals":[],"_faersSignals":[{"count":7,"reaction":"EYE IRRITATION"},{"count":7,"reaction":"OCULAR HYPERAEMIA"},{"count":5,"reaction":"DRUG INEFFECTIVE"},{"count":4,"reaction":"EYE PAIN"},{"count":3,"reaction":"PRODUCT QUALITY ISSUE"},{"count":3,"reaction":"WRONG TECHNIQUE IN PRODUCT USAGE PROCESS"},{"count":2,"reaction":"DRUG INEFFECTIVE FOR UNAPPROVED INDICATION"},{"count":2,"reaction":"NO ADVERSE EVENT"},{"count":2,"reaction":"OFF LABEL USE"},{"count":2,"reaction":"PRODUCT SUBSTITUTION ISSUE"}],"_approvalHistory":[],"publicationCount":32,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Lumigan® UD","Lumigan"],"phase":"marketed","status":"active","brandName":"Bimatoprost Ophthalmic Solution","genericName":"Bimatoprost Ophthalmic Solution","companyName":"Allergan","companyId":"allergan","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Bimatoprost is a prostaglandin F analog that binds to prostaglandin F receptors in the eye to increase uveoscleral outflow of aqueous humor, thereby lowering intraocular pressure. Used for Glaucoma, Ocular hypertension.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":1,"withResults":1},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}